<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964638</url>
  </required_header>
  <id_info>
    <org_study_id>S12-01613</org_study_id>
    <nct_id>NCT01964638</nct_id>
  </id_info>
  <brief_title>Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.</brief_title>
  <official_title>Comparative Analysis of Software-based MRI-Ultrasound Image Fusion Against Cognitive Targeting of Multi-Parametric MRI Findings With Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single center trial to examine the rates of cancer diagnosis when using&#xD;
      computerized software to target suspicious lesions within the prostate identified on mpMRI.&#xD;
      The primary evaluation involves comparing the rate of cancer diagnosis when using&#xD;
      software-based MRI-Ultrasound image fusion guided biopsy to sample mpMRI findings to the use&#xD;
      of visual guided biopsy (cognitive or mental targeting) of the same target. The hypothesis&#xD;
      being tested is that fusion guided biopsy will increase detection prostate cancer within&#xD;
      mpMRI findings as compared to visual guided biopsy of these areas&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of rates of prostate cancer diagnosis</measure>
    <time_frame>One week after biopsy</time_frame>
    <description>The primary endpoint of the study is the evaluation of the rates of prostate cancer diagnosis using software based MRI-TRUS imaging fusion targeting of mpMRI lesions as compared to cognitive co-registration and targeting of mpMRI lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Rate of cancer diagnosis using targeted biopsy</measure>
    <time_frame>One week after biopsy</time_frame>
    <description>The secondary endpoint of the study is the evaluation of the rate of cancer diagnosis using targeted biopsy (software or cognitive targeting) as compared to standard of care prostate biopsy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Targeted Biopsy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment. Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment. All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy. As a result the study includes a single arm with direct comparison of biopsy techniques.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted Biopsy</intervention_name>
    <arm_group_label>Targeted Biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No previous diagnosis of adenocarcinoma of the prostate&#xD;
&#xD;
          -  No contraindication to prostate biopsy (e.g. coagulopathy, medical condition&#xD;
             prohibiting abstinence from anti-platelet or anticoagulation therapies, anatomical&#xD;
             considerations, anatomical considerations)&#xD;
&#xD;
          -  Active urinary tract infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior pelvic radiotherapy&#xD;
&#xD;
          -  Prior androgen deprivation therapy&#xD;
&#xD;
          -  Evidence urinary tract infection or significant urinary retention&#xD;
&#xD;
          -  Prostate instrumentation (e.g. prostate biopsy, transurethral prostate procedure)&#xD;
             within 2 months prior to mpMRI.&#xD;
&#xD;
          -  Contraindication to MRI (severe claustrophobia, indwelling metallic objects&#xD;
             incompatible with MRI, pacemaker)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samr S Taneja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Co-Director, Smilow Comprehensive Prostate Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Smilow Prostate Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>October 14, 2013</last_update_submitted>
  <last_update_submitted_qc>October 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NYU Langone Health</investigator_affiliation>
    <investigator_full_name>Samir Taneja, MD</investigator_full_name>
    <investigator_title>Co-Director, Smilow Comprehensive Prostate Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Prostate Biopsy</keyword>
  <keyword>Targeted Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

